• Ishikawa T, Uetake H, Murotani K et al. Genome-wide DNA copy-number analysis in ACTS-CC trial of adjuvant chemotherapy for stage III colonic cancer. Anticancer Res. 2016; 36: 853-860.
  • Sugimoto T, Matsumoto T, Hosoi T et al. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT). Osteoporos Int. 2015; 26: 765-774.
  • Iwase T, Yamamoto K, Ra E et al. Diurnal variations in blood flow at optic nerve head and choroid in healthy eyes: diurnal variations in blood flow. Medicine 2015; 94: e519.
  • Nakashima T, Sato H, Gyo K et al. Idiopathic sudden sensorineural hearing loss in Japan. Acta Oto-Laryngologica 2014; 134: 1158-1163.
  • Atagi S, Katakami N, Yoshioka H et al. Nested case control study of proteomic biomarkers for interstitial lung disease in Japanese patients with non-small-cell lung cancer treated with erlotinib: a multicenter phase IV study (JO21661). Clin Lung Cancer 2013; 14:407-417.
  • Negoro H, Kanematsu A, Doi M et al. Involvement of urinary bladder Connexin43 and the circadian clock in coordination of diurnal micturition rhythm. Nat Commun. 2012; 3: 809.
  • Ishiguro M, Mochizuki H, Tomita N et al. Study protocol of the SACURA trial: a randomized phase III trial of efficacy and safety of UFT as adjuvant chemotherapy for stage II colon cancer. BMC Cancer 2012; 12: 281.
  • Shoji S, Suzuki M, Tomono Y et al. Population pharmacokinetics of pregabalin in healthy subjects and patients with post-herpetic neuralgia or diabetic peripheral neuropathy. Br J Clin Pharmacol. 2011; 72: 63-76.
  • Sugano K, Matsumoto Y, Itabashi T et al. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol. 2011; 46: 724-735.
  • Yamaguchi K, Mandai M, Oura T et al. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 2010; 29: 1741-1752.
  • Yoshimura K, Kamoto T, Ogawa O et al. Medical mushrooms used for biochemical failure after radical treatment for prostate cancer: an open-label study. Int J Urol. 2010; 17: 548-554.
  • Yamashita S, Hbujo H, Arai H et al. Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb. 2008; 15: 292-303.
  • Ito M, Nishiyama H, Kawanishi H et al. P21-activated kinase 1: a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer. J Urol. 2007; 178: 1073-1079.
  • Watanabe D, Suzuma K, Matsui S et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005; 353: 782-792.
  • Sakai R, Matsui S, Fukushima M et al. Prognostic factor analysis for plaque psoriasis. Dermatology 2005; 211: 103-106.
  • Kanatsu-Shinohara M, Toyokuni S, Morimoto T et al. Functional assessment of self-renewal activity of male germline stem cells following cytotoxic damage and serial transplantation. Biol Reprod. 2003; 68: 1801-1807.